Arkolith/Insider Trading/GBT/Form 4

Farrow Jeffrey S

Chief Financial OfficerGlobal Blood Therapeutics, Inc. (GBT) · full profile →Form 4 · filed Oct 6, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
1 non-derivative · 13 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 5, 2022Disposed to issuer(D)27K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 5, 2022Disposed to issuer(D)42K——0
Oct 5, 2022Disposed to issuer(D)26K——0
Oct 5, 2022Disposed to issuer(D)15K——0
Oct 5, 2022Disposed to issuer(D)14K——0
Oct 5, 2022Disposed to issuer(D)9K——0
Oct 5, 2022Disposed to issuer(D)3K——0
Oct 5, 2022Disposed to issuer(D)10K——0
Oct 5, 2022Disposed to issuer(D)39K——0
Oct 5, 2022Disposed to issuer(D)39K——0
Oct 5, 2022Disposed to issuer(D)40K——0
Oct 5, 2022Disposed to issuer(D)35K——0
Oct 5, 2022Disposed to issuer(D)120K——0
Oct 5, 2022Disposed to issuer(D)29K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-033145) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML